Hepatitis B virus (HBV) infection is a significant public health problem affecting an estimated 400 million individuals worldwide (28). Patients who are chronically infected with HBV have an increased risk of morbidity and mortality from cirrhosis and primary hepatocellular carcinoma (HCC) (32). The treatments currently approved for chronic hepatitis B patients, including alpha interferon and four nucleoside analogues that inhibit viral DNA polymerase, are limited by low rates of sustained response, side effects, and the emergence of drug resistance (30).HBV is the prototype virus of the family Hepadnaviridae and infects primarily hepatocytes. It is a small-DNA virus that contains a relaxed circular (rc) partially double-stranded DNA genome (49). Unlike other mammalian DNA viruses, HBV replicates via reverse transcription of its pregenomic (pg) RNA (48). In marked contrast to retroviruses, HBV genomic DNA integration into host cellular chromosomes is not an essential step in its life cycle. Instead, upon infection, incoming viral rcDNA is transported into the nucleus of the hepatocyte and converted into episomal covalently closed circular (ccc)DNA, which serves as the template for the transcription of viral RNAs. The viral pgRNA is translated to produce both the core protein and the reverse transcriptase (RT) (48). The RT protein binds to the epsilon sequence within the pgRNA to prime viral DNA synthesis and initiate nucleocapsid assembly (52, 53). Subsequently, the viral polymerase converts the pgRNA into rcDNA. The nucleocapsids mature as rcDNA is formed and can either be enveloped and secreted out of cells or deliver their rcDNA into the nucleus to amplify nuclear cccDNA (14,39,56).HBV replication is regulated by many extra-and intracellular factors. For example, it has been known for a long time that HBV replication is cell density and/or cell cycle dependent (34,40,59). Specific hormones and inflammatory cytokines have been shown to modulate the virus replication in cultured cells and in vivo (15,17,20,21,35). Furthermore, HBV replication also appears to be influenced by certain pathological conditions. For example, coinfections with other hepatitis viruses, such as hepatitis A virus, hepatitis C virus (HCV), and hepatitis D virus, suppress HBV replication (41,50,55). Interestingly, despite the existence of integrated HBV DNA in the majority of HBV-related hepatocellular carcinomas, the replicative forms of HBV DNA are usually negative in most tumor cells. Consistent with this observation, most HCC-derived cell lines do not support HBV replication upon transfection of a wild-type HBV genome (42,47,54). Moreover, studies done with woodchuck hepatitis virus-infected woodchucks demonstrated that woodchuck hepatitis virus replication was largely eliminated in precancerous nodules (58). Those observations suggest that the activation of certain cellular oncogenic pathways can inhibit HBV replication. However, the molecular